zSpace, Inc. Announces Intention to Voluntarily Delist from Nasdaq and Deregister Its Common Stock with the SEC

zSpace intends to voluntarily delist from Nasdaq by approximately October 5, 2026, after its Nasdaq trading suspension began on April 28 and its appeal was denied on August 6. The company expects Section 12(b) deregistration by about December 24 and plans to file Form 15 in January 2027, immediately suspending SEC reporting obligations including 10-K, 10-Q and 8-K filings. Shares are expected to remain quoted OTC as ZSPC, but the company cautioned that continued broker-dealer market making is not assured, creating material liquidity and transparency risks for investors.

Analysis

ZSPC is transitioning from a distressed listed security into an illiquid, information-constrained OTC instrument. The key investable consequence is not the formal delisting itself but the planned suspension of periodic disclosure in early 2027: institutional ownership eligibility, broker research coverage, margin availability, and market-maker willingness can all deteriorate before that date. Any apparent savings in public-company costs are unlikely to receive a valuation multiple until investors can independently verify that liquidity preservation outweighs the loss of governance and reporting discipline.

The near-term setup is structurally unfavorable for residual long holders. Funds with exchange-listing, minimum-price, custody, or liquidity mandates may continue to exit into a shallow OTC market over the next 1-3 months, while bid-ask spreads and failed execution risk rise materially around the October and January procedural milestones. The absence of a disclosed strategic transaction, financing, or audited operating inflection means there is no identifiable catalyst to offset that forced-selling dynamic.

NDAQ has no meaningful earnings exposure; this is immaterial against its transaction, data, and listing-revenue base. The more relevant second-order read is for microcap investors: voluntary deregistration after an unsuccessful listing appeal should be treated as a governance/liquidity warning, not evidence of a turnaround. The contrarian case is a take-private, asset sale, or creditor-led recapitalization at a premium, but that requires a filing, financing commitment, or insider transaction; none is currently evidenced. Thesis is falsified by a binding strategic alternative, audited cash runway sufficient for at least 12 months, or a commitment to maintain SEC reporting beyond the planned suspension.

Key Decisions for Investors

• Avoid initiating or adding to ZSPC longs; for any legacy position, seek an orderly reduction before the expected October 2026 effective delisting rather than assuming continuous OTC liquidity.
• Do not short ZSPC absent borrow confirmation and executable OTC liquidity: the fundamental downside may be substantial, but borrow cost, recalls, sparse prints, and event-driven squeeze risk make the trade operationally unattractive.
• Set event alerts for the Form 25, any Form 15 filing, insider purchases, debt amendments, and an announced financing or strategic-review process. Reassess only if a transaction provides a firm value floor relative to the prevailing OTC quote.
• No actionable NDAQ position from this development. Treat any price reaction in NDAQ as noise unless accompanied by broader changes in Nasdaq listing standards, delisting volumes, or issuer-retention policy.